Off-target resistance mechanisms are led by the activation of an alternative molecular pathway able to fuel cancer cell survival and proliferation despite EGFR inhibition, such as HGF/MET axis activation and cell cycle aberrations, including CDK6 amplification or CDKN2A/B rearrangement [22], as reported in this case. This evidence concerns the gene CDK6 and cancer.